115 results
424B5
ENVB
Enveric Biosciences Inc
3 May 24
Prospectus supplement for primary offering
5:05pm
and Institute
Clinical Research
Stephen M. Stahl, M.D., Ph.D.
Director of Psychopharmacology for the California Department of State Hospitals
Clinical Research
424B5
ENVB
Enveric Biosciences Inc
11 Mar 24
Prospectus supplement for primary offering
12:35pm
Department of State Hospitals
Clinical Research
Sheila DeWitt, Ph.D.
Chair, President & CEO of DeuteRx, LLC; COO of Neuromity Therapeutics, Inc.; Founder
8-K
aqi3ubnwr
9 Feb 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:05am
8-K
bsp4f3b
22 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
EX-10.1
zmc x7nfzgq1bypw2
6 Nov 23
Entry into a Material Definitive Agreement
8:05am
8-K
EX-1.1
uktle41avngwsuikl6
1 Sep 23
Entry into a Material Definitive Agreement
5:26pm
424B3
7khkg lo83u6
12 Aug 22
Prospectus supplement
9:17am
8-K
EX-10.2
05y2qj
26 Jul 22
Enveric Biosciences Announces $8 Million Registered Direct Offering and Private Placement, Priced at a Premium to Market Under Nasdaq Rules
5:15pm